ORIC Pharmaceuticals, Inc. announced initial data for its PRC2 inhibitor ORIC-944, operational highlights for 2023, and anticipated upcoming milestones. As of December 10, 2023, the initial Phase 1b monotherapy data for ORIC-944, a potent and selective allosteric inhibitor of PRC2, in patients with metastatic prostate cancer demonstrated: Potential best-in-class drug properties, including clinical half-life consistent with preclinical prediction of >10 hours, which is superior to other PRC2 inhibitors and supports QD dosing; No signs of CYP autoinduction that is seen with first-generation PRC2 inhibitors; Robust target engagement with maximal decrease (=75%) in H3K27me3 in monocytes from peripheral blood samples at doses as low as 200 mg QD, with low inter-patient variability; and Favorable safety with only grade 1 and 2 treatment-related adverse events at dose levels corresponding with strong target engagement. Emerging profile with superior drug properties support advancement into combination development in prostate cancer with AR inhibitor(s).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.52 USD | -1.57% | +11.57% | -18.26% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.26% | 507M | |
+16.44% | 122B | |
+18.94% | 113B | |
+18.52% | 26.22B | |
-25.37% | 19.01B | |
-19.98% | 15.71B | |
-20.20% | 15.22B | |
-47.37% | 14.72B | |
+59.91% | 14.58B | |
+4.35% | 13.84B |
- Stock Market
- Equities
- ORIC Stock
- News ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944